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Topic 02 – Heart failure and cardiomyopathy
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Background ST2, an interleukin-1 (IL-1) receptor family member, is an
emerging biomarker promising to assess prognosis in various pathophysiolog-
ical conditions including heart failure (HF). The aim of this work was to
investigate the prognosis interest of this marker in ambulatory patients with
stable HF. 
Methods Patients were included in this study in 2010. All patients gave
informed consent. Clinical characteristics were registered and biomarkers
were assessed. Clinical outcomes were registered regularly by a clinical
follow-up or by phone by a dedicated physician. We use the prognostic score
of Lupon et al. including clinical data, NT pro-BNP, hs-c TnT and SST2
assay. Survival curves were built and data presented as means±SD when nor-
mally distributed. 
Results 180 patients (mean age 72.5y±12.5y) were included. Left ventric-
ular ejection fraction was 37.1%±14.2%. ST2 concentrations are strongly pre-
dictive of all cause mortality [HR 3.15 (95% CI: 1.46-6.8)] and cardiovascular
mortality [HR 4.28 (95% CI: 1.5-12.26)] regardless of NT pro-BNP concen-
trations. Estimation of the risk of all-cause and cardiovascular mortality was
significantly improved by adding SST2, NT pro-BNP and hs-c TnT levels to
clinical covariates. Risk of mortality was estimated using Cox proportionnal
hazard models. Discrimination, assessed by c-index, rose from 0.678 for the
clinical model to 0.715 after addition of biomarkers for prediction of all-cause
mortality. For cardiovascular mortality, c-index was improved from 0.703 to
0.753. Added value of biomarkers was also evaluated by reclassification anal-
ysis. Associated net reclassification improvement (NRI) [95% CI] for 48
months death were 0.395 [0.068-0.653], p=0.033 and 0.395 [0.068-0.653],
p=0.020 for all cause and cardiovascular death, respectively.
Conclusions SST2 appears as a promising prognostic biomarker. It could
provide additional information to natriuretic peptides
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Background Hypertrophic cardiomyopathy (HCM) is a disease character-
ized by cell disorganization with a matrix remodeling leading to fibrosis. 
Aim The purpose of our study was to investigate biological markers which
are the amino terminal pro peptide of type III collagen (PIIINP), a metallopro-
teinase (MMP3) involved in the regulation collagen and its specific tissue
inhibitor TIPM2. We included 107 patients and 175 controls. We studied the
association of serum levels of these markers with clinical, echocardiographic
and prognostic parameters.
Results In the study population, the mean age was 49 years, 60 were male,
75% were symptomatic (palpitations in 38% of cases, chest pain in 28% of
cases, syncope in 25% of cases) the rate of PIIINP was significantly higher in
patients compared with controls (361.92±41.6pg/mL vs 242.80±46.7ng/ml;
p=0.036). Same for themmP3 and TIMP2 levels (12.16±4.3pg/mL vs
10.4±3.78pg/mL and 63.4±23.5pg/mL vs 57.50±21.43pg/mL, respectively,
p=0.03). We note that themmP3 / TIMP2 ratio is correlated to left ventricular
(LV) mass and the left atrium volume (r=0.560, p=0.002, and r=0.633,
p=0.001 rspectively), the PIIINP is correlates to the maximum thickness of the
LV (r=0.466, p=0.002), to the global longitudinal Strain of the LV and its
mass (r=0.578, r=0.001 and r=0.490, p=0.003 respectively). Patients with a
history of syncope and episodes of non-sustained ventricular tachycardia, were
younger and had a significantly higher rate of PIIINP (432.5±34.6pg/mL vs
320.44±32.8pg/mL, p=0.002) and less LV GLS (-14.7±2.6% vs 16.7±3.2%,
p=0.0034).
Conclusion HCM is characterized by ventricular and atrial remodeling and
fibrosis related to the collagen accumulation that is reflected bymmP3/ TIMP2
ratio serum and the PIIINP concentration. These parameters were correlated
with LV function may represent potential risk factors for the ventricular dys-
rhythmia and LV dysfunction.
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Abstract 0074 – Figure: Kaplan Meier, all cause mortality.Pronostic score 
of Lupon et al (clinival and biomarkers)
